151 related articles for article (PubMed ID: 22344547)
1. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
[TBL] [Abstract][Full Text] [Related]
2. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
[TBL] [Abstract][Full Text] [Related]
3. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China.
Wang S; Nie J; Wang Y
Virus Res; 2011 Jan; 155(1):137-46. PubMed ID: 20875470
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
[TBL] [Abstract][Full Text] [Related]
6. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
[TBL] [Abstract][Full Text] [Related]
8. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
[TBL] [Abstract][Full Text] [Related]
9. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
10. Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy.
Hu X; Hu Y; Zhao C; Gao H; Greene KM; Ren L; Ma L; Ruan Y; Sarzotti-Kelsoe M; Montefiori DC; Hong K; Shao Y
Sci Rep; 2017 Apr; 7():46308. PubMed ID: 28387330
[TBL] [Abstract][Full Text] [Related]
11. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
12. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
13. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
[TBL] [Abstract][Full Text] [Related]
14. Specificities of broadly neutralizing anti-HIV-1 sera.
Binley J
Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
[TBL] [Abstract][Full Text] [Related]
15. Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.
OuYang Y; Sun J; Huang Y; Lu L; Xu W; Hu X; Hong K; Jiang S; Shao Y; Ma L
Virol J; 2013 Jan; 10():10. PubMed ID: 23289760
[TBL] [Abstract][Full Text] [Related]
16. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
[TBL] [Abstract][Full Text] [Related]
17. HIV type 1 B'/C recombinant (CRF07_BC) in virologic noncontrollers elicits neutralizing antibodies against heterologous but not autologous viruses.
Sun J; Ma L; Jiang S; Shao Y
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):237-9. PubMed ID: 20156107
[No Abstract] [Full Text] [Related]
18. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
[TBL] [Abstract][Full Text] [Related]
19. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
[TBL] [Abstract][Full Text] [Related]
20. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM
J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
